恶性疟原虫175KDa红细胞结合抗原与其受体相互作用分子机制的研究

发布时间：2018-05-26 15:51

  本文选题：中医药 + 恶性疟原虫EBA-175　； 参考：《第一军医大学》2005年硕士论文

【摘要】：一、研究背景与目的 疟疾是危害人类健康的虫媒传染病,广泛流行于热带和亚热带一些发展中国家。近年来,由于疟原虫抗药性和蚊媒耐药性的日益增强和广泛扩散,加之一些现代经济和社会因素的影响,使疟疾(尤其是恶性疟原虫)的流行有复燃趋势,急性感染病人越来越多,而可供选择的廉价、有效的化疗药物越来越少,从而使疟疾的防治面临严峻挑战。 恶性疟原虫的175-KDa红细胞结合抗原(EBA-175)自1985年由Camus和Hadley首次报道以来,经大量免疫学实验研究和流行病学调查证明:其既是疟疾疫苗的候选抗原,也是疟疾的特异诊断抗原。其位于裂殖子尖端微线体,与血型糖蛋白A(GPA)分子上o~-糖苷键寡糖的Neu5Ac(α2-3)-Gal决定簇结合,能够有效抑制裂殖子入侵红细胞。EBA-175与受体GPA结合点是位于氨基末端富含半光氨酸的Ⅱ区,该区F2结构域的抗体能够阻断该分子与GPA的反应并能抑制裂殖子入侵红细胞,表明该区域对疟原虫的致病具有功能重要性。这就为疟疾的发病机制提出了新的学说,亦为其预防和治疗提出了新的契入点。 自上世纪50年代以来,我国在中医药防治疟疾方面取得了丰硕的成果,尤其是应用青蒿素治疗恶性疟疾取得优良疗效的研究。为中医药抗疟铺开了光明
[Abstract]:I. the background and purpose of the research Malaria is an insect-borne infectious disease that is harmful to human health and is widely prevalent in some developing countries in the tropics and subtropics. In recent years, the increasing and widespread spread of malaria resistance and mosquito resistance, coupled with the impact of modern economic and social factors, has led to a resurgence of malaria, especially Plasmodium falciparum, There are more and more patients with acute infection, and the cheap and effective chemotherapeutic drugs available are becoming less and less, which makes the prevention and treatment of malaria face severe challenges. The 175-KDa erythrocyte binding antigen (EBA-175) of Plasmodium falciparum was first reported by Camus and Hadley in 1985. It has been proved by a large number of immunological experiments and epidemiological investigations that it is not only a candidate antigen for malaria vaccine, but also a specific diagnostic antigen for malaria. It is located at the tip of merozoite and binds to Neu5AcA (伪 2-3)-Gal determinant) of oligosaccharide on the blood group glycoprotein Agna. It can effectively inhibit the merozoite invasion of erythrocyte. EBA-175 and receptor GPA binding site is located at the amino end of the 鈪，

本文编号：1937829